1994 Volume 42 Issue Supplement4 Pages 337-341
Bacteriological and clinical studies on biapenem (BIPM), a new carbapenem antibiotic, were performed and the following results were obtained.
The minimum inhibitory concentrations (MICs) of BIPM, imipenem (IPM), cefpirome (CPR) and ceftazidime (CAZ) against 73 isolates, methicillin-sensitive Staphylococcus aureus (MSSA)(10 strains), Escherichia coli (14 strains), Klebsiella pneumoniae (15 strains), Pseudomonas aeruginosa (19 strains) and Acinetobacter calcoaceticus (15 strains), were determined according to the standard procedure described by the Japan Society of Chemotherapy.
The isolates of MSSA were inhibited at BIPM concentration of 0.39μg/ml or less and the MICs of BIPM was almost equal to that of IPM. The MICs of BIPM against E. coli and K. pneumoniae were inferior to those of CPR, while equal to those of IPM. BIPM showed the highest activity against. P. aeruginosa and A. calcoaceticus in the agents tested.
BIPM was administered to 2 patients with pneumonia and 2 with bronchopneumonia at a daily dose of 600 to 1200mg, 2 or 3 times a day for 7 to 15 days. The clinical effect was excellent in 2 cases, good in 1 and fair in 1.
No side effects were observed during the treatment in 4 patients. As to abnormal laboratory findings, an elevation of eosinophil count was observed in one case.
The above results suggest that BIPM is considered to be a useful drug for treatment of respiratory infections.
